1299. Clinical, Biochemical, and Pathological Profiles of 5464 Egyptian Chronic Hepatitis C Infected Patients
Session: Poster Abstract Session: Viral Epidemiology
Saturday, October 22, 2011
Room: Poster Hall B1
Background: In Egypt, hepatitis C Virus (HCV) is highly endemic (10% of general population), about 91% of them are infected with HCV genotype 4. However, data of HCV-specific burden disease for Egypt are scarce. Detailed baseline demographic, biochemical, and histological features of HCV patients might have major implications in designing optimal strategies for antiviral therapy, and hence better qualities for patient care. 

Methods:  Our aim is to identify clinical, biochemical and pathological features of chronic HCV patients as a step to optimize and standardize the required information about HCV population in Egypt. We analyzed retrospective data of 5464 HCV-antibody and PCR positive patients attending pretreatment assessment at one of the National Treatment Reference Centers, Cairo, Egypt.

Results:  Demographic characteristics and laboratory profile of the chronic HCV patients are presented in table 1. Egyptian chronic HCV patients are mostly males in their productive age. Most patients had mild elevation of liver enzymes, low viral load, and low AFP levels.  Liver biopsy revealed A1 and A2 in 60% and 32% of patients respectively. Almost 80% of the patients had ≤ F2 and only 7.3 % of the patients had F4 according to the METAVIR score. Meta regression demonstrated that advanced stages of fibrosis were significantly correlated with the platelet count, AST/ALT ratio, AFP levels and BMI (p ≤ 0.001). However there was no correlation with viral load. 

Conclusion: To our knowledge, this study is the first to include this huge number of chronic HCV patients on a nationwide scale, providing us with the demographic, biochemical, and histological characteristics in chronic hepatitis C (genotype 4) patients.

Table 1 Demographic characteristics and laboratory profile of the chronic HCV patients.

Baseline Profile

Mean ±SD

Median

Age(years)

41.56±9.85

42.00

BMI(kg/m2)

28.12±4.32

28.03

Hb (g/dl)

14.12±1.54

14.2

WBC(x103/cmm)

6.47±1.83

6.20

PLT(x103/μL)

214.28±63.29

208.00

AST (U/L)

56.77± 38.79

46

ALT (U/L)

63.25± 42.92

52

Albumin (g/dl)

4.22±0.47

4.20

Glucose (mg/dl)

99.43±28.93

93.00

AFP (ng/dl)

16.46±10.26

3.30

HCV-RNA(IU/ml)

1,34± 1,27 (x106)

97,5 (x103)

 



Subject Category: C. Clinical studies of bacterial infections and antibacterials including sexually transmitted diseases and mycobacterial infections (surveys, epidemiology, and clinical trials)

Tahany Awad, MD1, Naglaa Zayed, MD2, Wafaa El-Akel, MD2, Rabab Salama, MD2, Mahasen Mabrouk, MD2 and Mohamed El-Beshlawy , MD3, (1)Cochrane Hepato.Biliary Group, Copenhagen, Denmark, (2)Faculty of Medicine, Endemic Medicine and Hepatology Department, Cairo, Egypt, (3)Endemic Medicine and,Hepatology Departement, Cairo University, Cairo, Egypt

Disclosures:

T. Awad, Hoffmann-La Roche Ltd.: Speaker's Bureau, Speaker honorarium

N. Zayed, None

W. El-Akel, None

R. Salama, None

M. Mabrouk, None

M. El-Beshlawy , None

See more of: Viral Epidemiology
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.